Clinical Trials Logo

Clinical Trial Summary

Single-dose, open-label, two-period crossover study of ABT-143


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science


Related Conditions & MeSH terms


NCT number NCT00719693
Study type Interventional
Source AstraZeneca
Contact
Status Completed
Phase Phase 1
Start date July 2008

See also
  Status Clinical Trial Phase
Completed NCT00728780 - Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Capsules Relative to That From Co-administration of ABT-335 and Rosuvastatin for the 5/45mg Dosage Form. Phase 1